Tags : Moberg Pharma

Taisho Signs an Exclusive License Agreement with Moberg Pharma to

Shots: Moberg to receive $5M up front, $50M as development, regulatory & commercial milestone along with supply fees & royalties on sales. Taisho to get exclusive right to develop, register & commercialize MOB-015 in Japan and will fund & conduct development and registration activities in Japan The agreement is the third major agreement for MOB-015, […]Read More

Bayer Signs an Exclusive License Agreement with Moberg Pharma for

 Shots: Moberg to receive $1.69M upfront, $56.39M milestone, royalties & supply fees based on sales of MOB-015. Bayer to get exclusive commercialization rights for MOB-015 in EU post completion of its P-III The focus of the agreement is to develop MOB-015 based on Moberg’s formulation of terbinafine offering therapies & for the advancement of dermatological […]Read More

Cipher Pharmaceuticals Signs Exclusive License Agreement with Moberg Pharma for

Shots: Moberg to receive $14.6M as upfront and milestone payments of $4.6M for development and regulatory ($0.5M initial payment) and $10M on commercialization of product Moberg will be responsible for manufacturing the product while Cipher will take care of marketing, distribution and sales after completion of P-III trial and registration Moberg’s MOB-015 is a topical […]Read More